



Eric Sock  
Principal

1225 17th Street, Suite 1300  
Denver, CO 80202  
+1 720 297 6112  
eric.sock@mercer.com  
www.mercer.com

Ms. Sara Snell  
Myriad Genetics, Inc.  
320 Wakara Way  
Salt Lake City, UT 84108

September 13, 2022

Subject: Medicare Part D Prescription Drug Creditable Coverage Analysis for 2023

Dear Sara:

This letter summarizes our analysis and results in determining whether the prescription drug benefit plans offered to Myriad Genetics, Inc.'s employees and retirees qualify as creditable prescription drug coverage. The results of the analysis enable Myriad to disclose to participants and to the Centers for Medicare & Medicaid Services (CMS) whether or not coverage is creditable as required by CMS provisions listed in regulation 42 CFR §423.56(e). The analysis required for this determination is a gross value test of Myriad's prescription drug benefit plans to determine if the plans meet or exceed the actuarial value of the benefit provided by standard Medicare Part D coverage.

Our analysis determined that PPO and CDHP plans (for SelectHealth and Regence) health plans pass the gross value test and qualify as providing creditable prescription drug coverage in 2023.

## Background

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) was enacted on December 8, 2003. Among many changes, the MMA introduced outpatient prescription drug coverage (Part D) beginning January 1, 2006.

Similar to Part B, Medicare-eligible beneficiaries who delay Part D enrollment will be required to pay late enrollment fees. For Part D, the fee is 1% of the national base premium for every month of delay. Late enrollment fees will be waived if the beneficiary had participated continuously (i.e., without a gap of 63 days or longer) in an employer plan that provided Creditable Coverage since first eligible for Part D enrollment. An employer plan is considered to be creditable if it passes the Gross Value Test (i.e., if its benefits, before considering participant contributions, are of actuarial value that equals or exceeds that of standard Part D benefits).

All employers are required annually to provide their participants who are enrolled in (or seeking to enroll in prescription drug benefits<sup>1</sup>), and are eligible for Medicare Part D, with Creditable Coverage Notices or Non-Creditable Coverage Notices, whichever applies. Participants eligible for Medicare Part D include the following, if enrolled in Medicare Part A or Part B:

- Retirees/COBRA qualified beneficiaries age 65 and older; age 65 and older dependents of retirees/COBRA qualified beneficiaries

---

<sup>1</sup> Employers are not required to provide Creditable Coverage notices to participants in employer-sponsored Prescription Drug Plans (PDPs) certified by CMS and Medicare Advantage plans (Medicare HMOs and PPOs) since these plans will provide the participants' Creditable Coverage notices

- Active employees age 65 and older; age 65 and older dependents of active employees
- Medicare-eligible disabled current or former employees; Medicare-eligible disabled dependents of current or former employees

For employer plans that do not provide prescription drug benefits, there are no requirements to provide Creditable/Non-Creditable Coverage Notices.

## Methodology and Assumptions

The creditable coverage test is applied to specific “benefit options.” The regulations define a benefit option as “a particular benefit design, category of benefits, or cost-sharing arrangement offered within a group health plan.” Based on this information, we evaluated Myriad’s benefit options described in Appendix A.

The calculations of expected plan costs for the Standard Part D Plan and Myriad’s benefit options for the gross value test use a proprietary model developed by Mercer. We performed sensitivity analyses to test a range of key assumptions that represent likely cost levels and utilization patterns of eligible populations.

Each benefit value was compared to the prescription Rx coverage for the 2023 Standard Part D plan used for testing creditable coverage as follows:

Standard Part D Plan for testing purposes <sup>2</sup>	
Deductible	\$505
Initial Coverage Limit	\$4,660
Initial Coverage Coinsurance	75%
Donut Hole (no coverage)	\$4,660 – \$10,516.25
Catastrophic Coverage	Participants pay 5% with minimum copays of \$4.15 for generic or preferred multi-source drug, and \$10.35 for other drugs

## Results

The table below is a numerical summary of the testing results. The expected eligible charges were derived from normative data for a Medicare-eligible individual. The gross Rx Plan Cost utilized Myriad’s plan designs for active employees and non-Medicare-eligible dependents of Medicare retirees. The drug costs, for testing purposes, are based on the assumptions described above.

---

<sup>2</sup> Note that the 2023 Standard Plan is the plan from the original 2003 legislation, not the enhanced benefits provided under the Affordable Care Act.

	Regence and SelectHealth PPO Copay Plan	Regence and SelectHealth CDHP Plan
<b>Expected 2023 Eligible Charges</b>	100%	100%
<b>Gross Benefit Test</b>		
A. Gross Rx Plan Cost	76.3%	59.4%
B. Gross Part D Cost	55.2%	55.2%
C. Creditable Coverage Margin (A. – B.)	21.2%	4.2%
Pass/Fail Creditable Coverage (PASS if A. > B.)	<b>PASS</b>	<b>PASS</b>

Because your PPO and CDHP plan's expected paid cost as a percentage of total cost exceed the corresponding Standard Part D plan paid cost percentage, these benefit options pass the gross value test and provide creditable coverage.

### Required Steps

The following are required steps by Myriad:

1. Distribute creditable coverage/non-creditable coverage notices to individuals before October 15, 2022.
2. Notify the Centers for Medicare and Medicaid Services (CMS) of the creditable coverage status of the plan on the CMS website by March 1, 2023 (within 60 days after the beginning date of the plan year).
3. If there are any changes to a plan design, the plan should be reviewed to determine if it still passes the Creditable Coverage Test.

### Important caveats and limitations of Mercer's analysis

In preparing this report, we have employed Mercer's proprietary creditable coverage software and tools. Mercer has prepared this letter exclusively for Myriad, regarding whether your 2023 plans qualify as providing creditable prescription drug coverage in 2023. We have relied on experts who developed this model, which we have customized for purposes of this engagement. This determination applies to Myriad's medical plans for the 2023 plan year. It does not predict a plan's ability to meet these requirements in the future. These determinations may not be used or relied upon by any other party or for any other purpose. Mercer is not responsible for the consequences of any unauthorized use.

In conducting our analysis, we have relied on information supplied by Myriad. Myriad is solely responsible for the validity, accuracy, and comprehensiveness of this information. If the data supplied is not accurate and complete, this determination may need to be either revised or withdrawn as no longer valid.

Page 4  
September 13, 2022  
Sara Snell  
Myriad Genetics, Inc.

All of our analyses, including estimates/determinations, are based on the information and data available at a point in time and the projections are not a guarantee of any financial or other results that might be achieved. Any projections are subject to unforeseen and random events and so must be interpreted as having a potentially wide range of variability from the estimates/determinations.

## **Actuarial Certification**

The actuarial determinations in this letter are in accordance with the Actuarial Standards of Practice (ASOPs) established by the Actuarial Standards Board (ASB) and with our understanding of the applicable laws and regulations.

I am available to answer any questions on the material contained in this letter, or to provide explanations or further details as may be appropriate. I am a member of the American Academy of Actuaries and meet its Qualification Standards to render the actuarial opinion contained in this letter.

Sincerely,

Erick Sock  
Principal, FSA, MAAA

Copy: Rob Benda  
Nikki Wallace  
Marvine Mercado  
Teri Davis  
Ethan Archibald

*It is important to note that while our consultants are very familiar with the design, administration and operation of employee benefit plans and the law applicable to those activities, Mercer is not a law firm. Therefore, our recommendations should not be construed as, nor are they intended to be, legal advice.*

**Appendix A: 2023 Plan Designs**

	Plan 1 - PPO		Plan 2 - CDHP	
	In-Network	Out-of-Network	In-Network	Out-of-Network
Medical Deductible - Individual	\$750	\$1,200	\$2,000	\$3,500
Medical Deductible - Family	\$1,500	\$2,400	\$4,000	\$7,000
Pharmacy Benefits	<u>Retail</u>	<u>Mail Order</u>	<u>Retail</u>	<u>Mail Order</u>
Deductible	N/A	N/A	Medical Deductible Applies	
Generic	\$15 Copay	\$37.50 Copay	\$10 Copay	\$25 Copay
Formulary Brand	\$30 Copay	\$75 Copay	\$35 Copay	\$87.50 Copay
Non-Formulary Brand	\$70 Copay	\$175 Copay	\$60 Copay	\$150 Copay
Specialty	\$150 Copay	Not Covered	\$100 Copay	Not Covered